VAIA
CORT icon

Virtus Alternative Investment Advisers’s Corcept Therapeutics CORT Stock Holding History

Virtus Alternative Investment Advisers’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-316
Closed -$8K – 58
2020
Q4 		$8K Sell
316
-304
-49% -$6.41K 0.12% 67
2020
Q3 		$11K Sell
620
-370
-37% -$5.9K 0.2% 119
2020
Q2 		$17K Buy
+990
New +$13.9K 0.27% 83

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Alternative Investment Advisers's CORT Position: Q1 2021 in Review

Virtus Alternative Investment Advisers sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 316 shares — an estimated $8K sold.

Virtus Alternative Investment Advisers first reported a position in CORT in Q2 2020 and held it in 3 quarters. The position peaked at $17K in Q2 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

  • Virtus Alternative Investment Advisers reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Virtus Alternative Investment Advisers sold 316 Corcept Therapeutics shares in Q1 2021, an estimated $8K.
  • Virtus Alternative Investment Advisers first reported a position in Corcept Therapeutics in Q2 2020 and held it in 3 quarters.
  • Virtus Alternative Investment Advisers's Corcept Therapeutics position peaked at $17K in Q2 2020.
  • 209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Virtus Alternative Investment Advisers's 13F filing for Q1 2021.